Business Wire

Firmware Supply Chain Company Binarly Raises $3.6 Million from WestWave Capital, Acrobator Ventures

22.6.2022 19:10:00 EEST | Business Wire | Press release

Share

Binarly Inc., a cybersecurity company building technology to address repeatable security failures in the firmware supply chain, today announced $3.6 million in seed funding from WestWave Capital and Acrobator Ventures. Prominent cybersecurity leaders Michael Sutton, Thomas 'Halvar Flake' Dullien, Jamie Butler, Ryan Permeh, Bryson Bort, Pedram Amini, Chris Ueland and David Mandel from Emerging Ventures also joined as investors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005392/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Founded in 2021, Binarly brings decades of research experience identifying hardware and firmware security weaknesses and threats. Based in Los Angeles, California, Binarly’s agentless, enterprise-class AI-powered firmware security platform helps protect from advanced threats below the operating system. The company’s technology solves firmware supply chain security problems by identifying vulnerabilities, malicious firmware modifications and providing firmware SBOM visibility without access to the source code. Binarly’s cloud-agnostic solutions give enterprise security teams actionable insights, and reduce the cost and time to respond to security incidents. (Graphic: Business Wire)

Binarly is co-founded by security pioneers Alex Matrosov and Claudiu Teodorescu, who previously worked on hardware and software security at NVIDIA, Intel Corp., ESET, BlackBerry, Cylance and FireEye. Matrosov, a highly regarded researcher who is regularly credited with major vulnerability discoveries, is co-author of Rootkits and Bootkits, a seminal book that explains how to understand and counter sophisticated, advanced threats buried deep in a machine’s boot process or UEFI firmware.

Binarly has built a SaaS platform for analyzing, understanding and responding to silent, currently undetectable security threats at the firmware layer. Using a combination of machine learning and deep code inspection at the binary level, Binarly enables security teams to have real visibility into hardware and firmware failures and a simple way to recover from sophisticated attacks below the operating system.

Binarly also developed its own technology for vulnerability management and protecting the firmware supply chain from repeatable failures. The company’s approach uses semantic properties of the binary code to improve detection accuracy by limiting the number of false positives.

So far this year, Binarly has coordinated the disclosure of 107 critical firmware security vulnerabilities affecting the entire enterprise device ecosystem. The company worked with security response teams at Insyde, AMI, Lenovo, Dell, HP, HPE, Siemens, Fujitsu, Atos, Intel, AMD and many other vendors to mitigate high-impact security issues across the computing landscape. Many of these vulnerabilities demonstrate the complexities of the firmware supply chain that negatively disrupt the timeline for patch delivery and identification of impacted parties.

“The current approach in the industry is to detect risks related to the firmware by leveraging the current version number of the firmware update against a public database of vulnerabilities and threats. This leads to firmware supply chain failures because known vulnerabilities that are not associated with a certain version number of a firmware release will not be detected thus keeping the 'doors' open for an attacker,” Matrosov said.

“Assessing the impact of a known firmware based vulnerability in a customer environment, at scale, is a problem without a viable solution. We have developed the FwHunt technology that adds semantic context around a known vulnerability to ensure detection while reducing false positives,” Teodorescu said.

Binarly plans to use the investment to speed up research and development initiatives, expand its world-class engineering team, and scale enterprise and device manufacturer adoption of its technologies.

Quotes from investors:

“We are excited to invest in founders Alex and Claudiu at Binarly. We have immense respect for their deep technical expertise and understanding of the firmware security market. We recognize that there are significant exposure issues in addressing firmware security vulnerabilities and we have strong conviction that Binarly will mitigate those concerns - both immediate and in the long term.” - Warren “Bunny” Weiss, Managing Partner, WestWave Capital.

“CISOs from critical infrastructure companies, hyperscalers, and cybersecurity experts rate firmware security as a top-three priority. In a world where IoT, edge devices and the mere size of firmware on devices significantly increases, it’s a matter of ‘when’ not ‘if’ new dominant security solutions are adopted. Why Binarly? They’ve got the best-in-class team discovering vulnerabilities no one else has found and managed to surround themselves with incredible experts.” - Mike Reiner, General Partner, Acrobator Ventures.

“It’s no secret that firmware security presents a growing challenge that needs to be solved. For far too long, hardware manufacturers have relied on security through obscurity and we’re now paying the price as attackers identify and exploit flaws that impact thousands of devices across the globe. Blindly trusting hardware manufacturers is a recipe for disaster. The Binarly team has the expertise and vision to finally execute on delivering a scalable solution to get this problem under control.” - Michael Sutton, Managing Partner, Stonemill Ventures.

About WestWave Capital:
WestWave Capital is an early-stage Venture Capital firm that invests in Seed and Series A Enterprise companies building deep technology solutions. The company’s investments focus on SaaS, Security, Cloud Infrastructure, Blockchain, Analytics, and IoT companies.

About Acrobator Ventures:
Acrobator Ventures is an operator-led venture capital fund focused on early stage tech in the Benelux & CIS operating out of Kiev and Amsterdam.

About Binarly:
Founded in 2021, Binarly brings decades of research experience identifying hardware and firmware security weaknesses and threats. Based in Los Angeles, California, Binarly’s agentless, enterprise-class AI-powered firmware security platform helps protect from advanced threats below the operating system. The company’s technology solves firmware supply chain security problems by identifying vulnerabilities, malicious firmware modifications and providing firmware SBOM visibility without access to the source code. Binarly’s cloud-agnostic solutions give enterprise security teams actionable insights, and reduce the cost and time to respond to security incidents.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Alex Matrosov
media@binarly.io
818.351.9637

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye